DERM at a glance
Journey Medical Corp (DERM, SEC CIK 1867066) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as June 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Journey Medical Corp (DERM) reported revenue of $61.2 million (up 11.1% from FY2024) and a net loss of $11.4 million. Diluted EPS was -$0.47.
- As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Journey Medical Corp (DERM) shares worth $13.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $61.2M
- +11.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 16 funds
- $13.1M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $19.0M, up $1.3M YoY, driven by Emrosi sales
- Operating loss $0.5M vs $1.5M YoY, operating margin -2.8% vs -8.7%
- Best performer Emrosi: $9.0M, up $4.1M; worst Qbrexza: $5.6M, down $1.8M
- Cash $22.3M vs $24.1M at December 31, 2025; nine-month operating cash use $2.3M
- Going-concern uncertainty, potential debt or equity financing needs, generic competition and Qbrexza coverage headwinds
Risk Factors
- No material changes to risk factors disclosed since the 2025 Form 10-K
- Carried-forward business risk: unidentified risks may materially adversely affect operations
- Carried-forward financial risk: risks may materially affect financial condition
- Carried-forward performance risk: risks may materially affect results of operations
AI summary of the DERM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- September 30, 2026 quarter results and corporate update announced by Journey Medical Corporation
- Financial details and management commentary contained in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- Q3 2026 revenue $19.0M, up 8% year over year, signaling continued commercial momentum
- Emrosi revenue $9.0M, up 84%, with approximately 40,000 prescriptions and stronger reimbursement trends
Item 2.02: Results of Operations and Financial Condition
- Journey Medical announced financial results for the three months ended June 30, 2026
- Corporate update and detailed results furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $18.5M, up 23% year over year, led by Emrosi revenue of $8.1M
- Emrosi prescriptions reached approximately 36,000, up from 30,000 in Q1 2026 and 27,000 in Q4 2025
Item 5.07: Submission of Matters to a Vote of Security Holders
- 2026 annual meeting reached quorum with 81% representation, including 6 million super-voting Class A shares
- Six directors elected through 2027, with Neil Herskowitz receiving the highest withheld vote count at 1,381,937
AI summaries of DERM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DERM
Don't miss the next DERM filing
- Alerts as it files. A push when DERM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DERM, by share count.
- Ask anything. An AI agent that reads every DERM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Toledano Miranda Jayne | A | Jun 25, 2026 | 10,000 | - |
| ROSENWALD LINDSAY A MD | A | Jun 25, 2026 | 10,000 | - |
| Pearce Michael Cooper | A | Jun 25, 2026 | 10,000 | - |
| Herskowitz Neil | A | Jun 25, 2026 | 10,000 | - |
| Smith Justin Adam | A | Jun 25, 2026 | 10,000 | - |
| Alloush Ramsey | A | Apr 22, 2026 | 46,863 | - |
| Maraoui Claude | A | Apr 22, 2026 | 82,915 | - |
| Alloush Ramsey | A | Apr 22, 2026 | 62,795 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $59.7M | $55.1M | $61.2M |
| Operating Income | -$2.1M | -$13.7M | -$8.2M |
| Net Income | - | -$14.7M | -$11.4M |
| Op. Margin | -3.5% | -24.8% | -13.3% |
| Net Margin | - | -26.6% | -18.7% |
| Balance Sheet | |||
| Total Assets | $76.8M | $80.2M | $94.6M |
| Equity | $20.4M | $20.1M | $31.9M |
| ROE | - | -73.1% | -35.9% |
| Per Share | |||
| EPS | $-0.21 | $-0.72 | $-0.47 |
| Cash Flow | |||
| Operating CF | $5.2M | -$9.1M | -$12.4M |
Source: XBRL data in Journey Medical Corp (DERM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DERM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 16 | $13.1M |
| Q2 2026 | 16 | $10.8M |
| Q1 2026 | 18 | $15.9M |
| Q4 2025 | 18 | $20.8M |
| Q3 2025 | 15 | $13.7M |
| Q2 2025 | 12 | $11.9M |
| Q1 2025 | 9 | $4.4M |
| Q4 2024 | 6 | $2.6M |
- Millennium Management+129.7K (+118%)
- Morgan Stanley+80.0K (+190%)
- Citigroup+6.8K (+167%)
- JPMorgan Chase & Co+5.2K (+1771%)
- State Street Corp+4.6K (+7%)
- Citadel Advisors LLC−30.7K (-37%)
- Bank of America Corp−23.1K (-55%)
- Goldman Sachs Group−5.4K (-6%)
- BlackRock−4.8K (-5%)
- Renaissance Technologies LLC−800 (-0%)
- Two Sigma Investments+240.8K
- D.E. Shaw & Co+12.8K
- AQR Capital Management−24.9K
- FMR LLC (Fidelity)−476
Source: 13F-HR filings on SEC EDGAR (aggregated from 110 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DERM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 25, 2026 | - | - | - |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 12, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 15, 2025 | Mar 31, 2025 | - | |
| SC 13G | May 13, 2025 | - | - | |
| 10-K | Mar 27, 2025 | Dec 31, 2024 | - | |
| SC 13G | Nov 29, 2024 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DERM SEC filings: frequently asked questions
Which institutions hold DERM stock?
As of September 30, 2026, the largest Journey Medical Corp (DERM) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.6 million), Two Sigma Investments ($1.6 million), Millennium Management ($1.6 million), Renaissance Technologies LLC ($1.6 million), Morgan Stanley ($835,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DERM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Journey Medical Corp (DERM) reported revenue of $61.2 million (up 11.1% from FY2024) and a net loss of $11.4 million. Diluted EPS was -$0.47. The figures come from the XBRL data in the 10-K.
What did DERM report in its latest 8-K?
Journey Medical Corp (DERM) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). September 30, 2026 quarter results and corporate update announced by Journey Medical Corporation.
What are the latest DERM SEC filings?
Journey Medical Corp (DERM) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on June 29, 2026.
What is DERM's SEC CIK number?
Journey Medical Corp (DERM)'s SEC Central Index Key (CIK) is 1867066. EDGAR lists every DERM filing under that number.
Ask anything about DERM
The research agent reads DERM's filings, financials, insider trades and 13F holders, then answers with sources.